This project aims to develop predictive tools to identify which melanoma patients will benefit from immunotherapy and which may develop resistance. By integrating multi-omic data — including clinical outcomes, RNA and DNA sequencing, multiplex immunohistochemistry, and other advanced technologies — we are building comprehensive models to guide treatment selection, improve response rates, and personalise care. Importantly, this work spans disease stages from stage II to IV and considers multiple treatment settings, including neoadjuvant, adjuvant, and metastatic therapy. By combining clinical insight with cutting-edge molecular profiling, our goal is to bring precision immunotherapy from discovery into practice.